基于双能CT的AI模型预测胃癌PD-1/PD-L1抑制剂联合化疗的疗效与预后:一项多中心研究
本研究纳入344例胃腺癌患者,基于双能CT定量参数与影像组学构建logistic回归模型,预测PD-1/PD-L1抑制剂联合化疗的疗效与预后;模型在四个数据集AUC为0.827、0.803、0.775、0.781,校准良好,高风险组及iRECIST无应答者OS与PFS显著更差。
要点
- 双能CT影像组学logistic回归模型在训练集AUC 0.827,验证集0.803,外部验证集0.775,跨平台验证集0.781。
- 模型预测与观察值校准良好,Hosmer-Lemeshow检验P值分别为0.291、0.162、0.918、0.281。
- 高风险组较低风险组OS和PFS显著更差,iRECIST无应答者较应答者OS和PFS显著更差(均P<0.05)。
核心结论
- 基于双能CT的影像组学模型可预测胃癌患者接受免疫联合化疗的疗效与预后,支持个体化治疗规划及治疗策略优化。
研究设计与样本
- 多中心研究,共纳入344例胃腺癌患者,分为训练集、验证集、外部验证集和跨平台验证集;以iRECIST为标准将患者分为应答者与无应答者;评估常规CT和双能CT的临床特征及定性和定量影像生物标志物;使用五种机器学习算法整合影像生物标志物模型、独立临床预测因子和双能CT模型,并构建logistic回归模型。
关键影像表现/征象
- 高风险组较低风险组OS和PFS显著更差。
- iRECIST无应答者较应答者OS和PFS显著更差(均P<0.05,χ2=3.98-13.67)。
诊断标准与关键数值
- logistic回归模型为最优机器学习模型,训练集AUC 0.827(95%CI:0.764-0.891),验证集AUC 0.803(95%CI:0.695-0.910),外部验证集AUC 0.775(95%CI:0.641-0.909),跨平台验证集AUC 0.781(95%CI:0.614-0.948)。
- 训练集与其他数据集AUC无显著差异(DeLong检验:P=0.698、0.488、0.646)。
- 校准曲线Hosmer-Lemeshow检验P值:训练集0.291、验证集0.162、测试集1为0.918、外部测试集2为0.281;Brier评分0.158-0.197。
- DCA净获益阈值范围:训练集0.02-0.95,验证集0.19-0.79,测试集1为0.04-0.66,外部测试集2为0.03-0.76;50%阈值时净获益分别为0.160、0.218、0.120、0.314。
- 亚组分析证实模型泛化性稳健(所有P>0.05)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to evaluate the ability of dual-energy CT (DECT) quantitative parameters and radiomics to predict treatment efficacy and prognosis in gastric cancer patients receiving PD-1/PD-L1 inhibitor-based combination chemotherapy.
METHODS: This study enrolled a total of 344 patients with gastric adenocarcinoma, divided into training, validation, external-validation, and cross-platform validation sets. Based on the Immune Response Evaluation Criteria in Solid Tumors (iRECIST) for immunotherapy, patients were classified as responders or non-responders. Clinical features and qualitative and quantitative imaging biomarkers from conventional CT and DECT were evaluated. Five machine learning algorithms were used to integrate imaging biomarker models, independent clinical predictors, and DECT models. A logistic regression model was then constructed based on the integrated data. Model performance was assessed using receiver operating characteristic (ROC) analysis, calibration curves, decision curve analysis (DCA), and the IDI and NRI indices, with subgroup analysis performed to validate the model's generalizability. Kaplan-Meier (KM) survival analysis was conducted to evaluate the association between imaging biomarkers and progression-free survival (PFS) and overall survival (OS).
RESULTS: The logistic regression model was identified as the optimal machine learning model, with AUCs of 0.827 (95% CI: 0.764-0.891), 0.803 (95% CI: 0.695-0.910), 0.775 (95% CI: 0.641-0.909), and 0.781 (95% CI: 0.614-0.948) across the four sets. No significant differences in AUC were observed between the training set and the other sets (DeLong test: P = 0.698, 0.488, and 0.646), indicating stable model performance. Calibration curves indicated good agreement between predicted and observed outcomes across all sets, with Hosmer-Lemeshow test P-values of 0.291, 0.162, 0.918, and 0.281 for the training, validation, test 1, and external test 2 sets, respectively. Brier scores (0.158-0.197) further confirmed high predictive accuracy. DCA showed positive net benefit across wide threshold ranges: 0.02-0.95 (training), 0.19-0.79 (validation), 0.04-0.66 (test 1), and 0.03-0.76 (external test 2). At a 50% threshold, net benefits were 0.160, 0.218, 0.120, and 0.314. Subgroup analyses confirmed robust generalizability (all P > 0.05). KM curves demonstrated that patients in the high-risk group had significantly worse OS and PFS compared with those in the low-risk group. Similarly, patients classified as non-responders by iRECIST had significantly poorer OS and PFS than responders (all P < 0.05, χ2 = 3.98-13.67).
CONCLUSION: The DECT-based radiomics model can predict treatment response and prognosis in gastric cancer patients receiving immunotherapy combined with chemotherapy and support individualized treatment planning and optimization of therapeutic strategies.
引用
- Fan S, Zheng Y, Yuan M, et al. Prediction of efficacy and prognosis of PD‑1/PD‑L1 inhibitor combination chemotherapy for gastric cancer using an AI model based on dual‑energy CT: A multicenter study. Eur J Radiol. 2026. PMID: 42372561. doi:10.1016/j.ejrad.2026.113013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。